BioVersys AG (XSWX:BIOV) Total Receivables: CHF0.90 Mil (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.00
View Full Analysis

What is BioVersys AG Total Receivables?

BioVersys AG XSWX:BIOV 4 Total Receivables is CHF0.90 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Total Receivables for the quarter that ended in Dec. 2025 was CHF0.90 Mil.

BioVersys AG Total Receivables Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Receivables Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Receivables
0.03 0.90

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Receivables 0.00 0.03 2.21 0.90
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of CHF0.90 Mil mean?
BioVersys AG (XSWX:BIOV) has a Total Receivables of CHF0.90 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Total Receivables too high?
BioVersys AG's current Total Receivables is CHF0.90 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Receivables compare to VRTX and REGN?
BioVersys AG's Total Receivables of CHF0.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on BioVersys AG and its competitors. BioVersys AG's current Total Receivables is CHF0.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Total Receivables of CHF0.90 Mil. The current Total Receivables is CHF0.90 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Total Receivables is CHF0.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.00
Price